文献速递慢性肾脏病水电解质与酸碱

非奈利酮联合SGLT2抑制剂对比单药治疗CKD的心肾结局

Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该回顾性队列研究基于TriNetX数据库纳入2021至2023年美国多中心CKD患者,比较非奈利酮联合SGLT2抑制剂与各自单药治疗的心肾结局。联合治疗组主要不良肾脏事件(MAKE)风险显著低于非奈利酮单药(aHR 0.20)和SGLT2i单药(aHR 0.44),全因死亡和ESRD风险亦降低,但高钾血症风险高于SGLT2i单药。

要点

  • 联合治疗较非奈利酮单药显著降低MAKE风险(aHR 0.20)。
  • 联合治疗较SGLT2i单药显著降低MAKE风险(aHR 0.44)。
  • 联合治疗高钾血症风险高于SGLT2i单药(aHR 1.36)。

核心结论

  • 在CKD患者中,非奈利酮联合SGLT2抑制剂相比单药治疗与更低的MAKE和全因死亡风险相关。
  • 联合治疗的高钾血症风险需引起警惕。

研究设计与样本

  • 回顾性队列研究,使用美国多中心TriNetX数据库,纳入2021年7月9日至2023年11月30日期间成人CKD患者。

主要发现

  • 匹配后联合组MAKE风险低于非奈利酮单药(aHR 0.20;95%CI 0.09-0.45)和SGLT2i单药(aHR 0.44;95%CI 0.22-0.89)。
  • 联合组全因死亡和ESRD风险均低于非奈利酮或SGLT2i单药。
  • 联合组与单药组MACE风险相似。
  • 联合组高钾血症风险高于SGLT2i单药(aHR 1.36;95%CI 1.08-1.71)。

临床怎么用

  • 对CKD患者可考虑非奈利酮与SGLT2抑制剂联合治疗以降低MAKE和死亡风险。
  • 联合治疗期间应监测血钾,警惕高钾血症。

局限性

  • 回顾性队列设计可能存在残余混杂。
  • 联合组与非奈利酮组样本量较小,SGLT2i组样本量较大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and finerenone each improve kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD). This study compares the association between combined therapy versus monotherapy with SGLT2i or finerenone and the kidney, cardiovascular and mortality outcomes in CKD patients. METHODS: This retrospective cohort study included adults ≥18 years with CKD between 9 July 2021, and 30 November 2023 from multiple centers in the USA, utilizing the TriNetX database. Exposures included treatment with finerenone, SGLT2i or a combination of both. The primary outcome was major adverse kidney events (MAKE). Secondary outcomes included all-cause mortality, major adverse cardiac events (MACE) and end-stage renal disease (ESRD). RESULTS: A total of 853 patients were included in the combined group [mean (±standard deviation) age, 66.7 ± 11.4 years; 34.9% female], 942 in the finerenone group (mean age, 68.2 ± 11.4 years; 45.8% female) and 45 948 in the SGLT2i group (mean age, 70.2 ± 11.8 years; 41.4% female). After matching, the combined group had less MAKE compared with finerenone monotherapy [adjusted hazard ratio (aHR) 0.20; 95% confidence interval (CI) 0.09-0.45] or SGLT2i monotherapy (aHR 0.44; 95% CI 0.22-0.89). The hazards of all-cause mortality and ESRD were also lower in the combined group compared with either finerenone or SGLT2i alone, while hazard of MACE was similar between the combined and monotherapy groups. The combined group had higher risk of hyperkalemia compared with SGLT2i monotherapy (aHR = 1.36; 95% CI 1.08-1.71). CONCLUSION: Combined therapy with finerenone and SGLT2i is associated with less MAKE and all-cause mortality in CKD patients compared with monotherapy. However, the risk of hyperkalemia with finerenone warrants caution.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Chuang MH, Wang HY, Kan WC, et al. Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD. Nephrol Dial Transplant. 2025. PMID: 40199739. doi:10.1093/ndt/gfaf064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。